Abstract
Currently, COVID-19 has been reported in nearly all countries globally. To date, little is known about the viral shedding duration, clinical course and treatment efficacy of COVID-19 near Hubei Province, China. This multicentre, retrospective study was performed in 12 hospitals in Henan and Shaanxi Provinces from 20 January to 8 February 2020. Clinical outcomes were followed up until 26 March 2020. The viral shedding duration, full clinical course and treatment efficacy were analysed in different subgroups of patients. A total of 149 COVID-19 patients were enrolled. The median age was 42 years, and 61.1% (91) were males. Of them, 133 (89.3%) had fever, 131 of 144 (91%) had pneumonia, 27 (18.1%) required intensive care unit (ICU) management, 3 (2%) were pregnant, and 3 (2%) died. Two premature newborns were negative for SARS-CoV-2. In total, the median SARS-CoV-2 shedding period and clinical course were 12 (IQR: 9-17; mean: 13.4, 95% CI: 12.5, 14.2) and 20 (IQR: 16-24; mean: 21.2, 95% CI: 20.1, 22.3) days, respectively, and ICU patients had longer median viral shedding periods (21 [17-24] versus 11 [9-15]) and clinical courses (30 [22-33] vs. 19 [15.8-22]) than non-ICU patients (both p < .0001). SARS-CoV-2 clearances occurred at least 2 days before fatality in 3 non-survivors. Current treatment with any anti-viral agent or combination did not present the benefit of shortening viral shedding period and clinical course (all p > .05) in real-life settings. In conclusion, the viral shedding duration and clinical course in Henan and Shaanxi Provinces were shorter than those in Hubei Province, and current anti-viral therapies were ineffective for shortening viral shedding duration and clinical course in real-world settings. These findings expand our knowledge of the SARS-CoV-2 infection and may be helpful for management of the epidemic outbreak of COVID-19 worldwide. Further studies concerning effective anti-viral agents and vaccines are urgently needed.
Keywords: Coronavirus disease 2019 (COVID-19); Henan Province; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Shaanxi Province; anti-viral efficacy; clinical course; epidemiology.
【저자키워드】 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Coronavirus disease 2019 (COVID-19), Clinical course, Henan Province, Shaanxi Province, anti-viral efficacy, epidemiology., 【초록키워드】 COVID-19, Treatment, coronavirus disease, severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, Coronavirus disease 2019, Efficacy, Vaccine, coronavirus, intensive care, Pneumonia, Epidemiology, knowledge, SARS-COV-2 infection, hospital, Infection, intensive care unit, viral shedding, outcome, severe acute respiratory syndrome Coronavirus, clinical outcomes, ICU, Anti-viral, anti-viral agent, China, Retrospective study, Newborn, Clinical course, Viral, outbreak, clinical, management, Fever, Premature, ICU Patients, multicentre, respiratory, Anti-viral therapy, fatality, Combination, pregnant, COVID-19 patient, clinical courses, Non-survivors, acute respiratory syndrome, acute respiratory syndrome coronavirus, median age, non-ICU, non-ICU patients, SARS-CoV-2 clearance, country, effective, benefit, ICU patient, males, the epidemic, current, enrolled, occurred, died, reported, required, was performed, analysed, median, concerning, expand, non-ICU patient, subgroups of patients, the median, the SARS-CoV-2, 【제목키워드】 COVID-19, Treatment, Efficacy, clinical, multicentre, Course,